Systemic lupus erythematosus (SLE) is a chronic inflammatory disease with a relapsing and remitting course, which is often treatable with immunosuppressive therapy. However, we describe a patient with severe and refractory thrombotic thrombocytopaenic purpura (TTP) secondary to SLE that did not respond to high dose corticosteroids, cyclophosphamide (CyC), vincristine, rituximab, and plasmapheresis. She eventually required haematopoietic stem cell transplantation (HSCT) to bring the disease under control. She is in disease remission three years post-stem cell transplantation. HSCT is a possible treatment option for severe and refractory SLE when conventional therapy has failed. HSCT for other rheumatologic diseases is also reviewed.
INTRODUCTION
SLE is a chronic, multifaceted inflammatory disease that can affect every organ system of the body. SLE is protean in its manifestations and follows a relapsing and remitting course.
CASE REPORT
A 29-year-old Chinese lady, with no past medical history, first presented with acute fever of one day, associated with swelling and pain over the wrist joints, small joints of the hands, and petechial rashes over both upper extremities. She was hypertensive with a blood pressure of 180/115mmHg, pulse rate of 85 beats per minute and non-toxic looking. The remainder of the physical examination was unremarkable.
Her investigations were as follows (normal values in parenthesis): haemoglobin level was 8.2g/ dL (12-16g/dL), total white cell count was 2.92 x 10 9 /L (4-10 x 10 9 /L) and platelet was 58 x 10 9 /L (140-440 x 10 9 /L). Absolute lymphocyte count was 1.06 x 10 9 /L (1-3 x 10 9 /L). Serum iron was 3umol/L (11-27umol/L), total serum iron binding capacity was 35umol/L (39-60umol/L), transferrin saturation was 8.6% (21-54%), serum ferritin was 102ug/L (7.6-179ug/L), serum folate was 14.7nmol/L (4.8-37.4nmol/L) and serum vitamin B12 levels was 165pmol/L (145-637pmol/L). Peripheral blood film showed few elliptocytes and fragmented cells. Haemoglobin electrophoresis demonstrated alpha thalassaemia. Bone marrow demonstrated moderate cellularity with mild stromal lysis and atypical megakaryocytes.
Her renal function was deranged with serum urea of 8.6mmol/L (2.8-7.7mmol/L) and serum creatinine of 159umol/L (40-85umol/L), measured creatinine clearance of 33ml/min (70-150ml/min). Liver function was normal except for hypoalbuminemia Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 of 28g/L (37-51g/L). 24-hour urine total protein was 0.889g/day (0-0.15g/day), total serum cholesterol was 4.6mmol/L, low density lipoprotein was 2.93mmol/L, and high density lipoprotein was 1.08mmol/L. Serum immunoglobulins (Ig) were normal. Microscopic haematuria was present with urine dysmorphic red blood cells 100 x 10 3 /ml (0-8 x 10 3 /ml). Renal biopsy was consistent with diffuse lupus nephritis, class 4-global (active), with features of microscopic thrombotic microangiopathy. Ultrasound of the kidneys showed bilaterally raised renal echogenicity, in keeping with renal impairment. Renal artery or vein stenosis was not seen.
Positive autoimmune markers included the following: anti-nuclear antigen (ANA) 1/400 with a homogenous pattern and double-stranded deoxyribonucleic acid (dsDNA) >500IU (<30IU). Hypocomplementaemia was present, i.e. C3 levels 0.21g/L (0.45-0.83g/L) and C4 0.03g/L (0.11-0.41g/ L). Anticardiolipin IgM and IgG, lupus anticoagulant, and anti-Ro antibodies were negative.
A diagnosis of SLE with renal and haematological involvement was made. This diagnosis was based on the presence of pancytopenia, positive ANA/dsDNA, and presence of lupus nephritis demonstrated on the renal biopsy. She was treated for three days with intravenous (IV) pulsed methylprednisolone 500mg once a day, followed by IV CyC 1,500mg once (1g/m 2 ) due to the presence of rapidly progressive glomerulonephritis (based on the presence of acute renal impairment). Despite maximal doses of atenolol, nifedipine (longacting), terazosin, telmisartan, and perindopril, her blood pressure remained persistently high. Pheochromocytoma was excluded via normal 24hour urine catecholamines and metanephrines, whilst hyperaldosteronism was excluded via normal serum aldosterone and renin-aldosterone ratio. She was then started on IV glyceryl trinitrate infusion and IV labetalol infusion, but this also failed to control her blood pressure.
At this time, her platelet count decreased from 143 x 10 9 /L to 21 x 10 9 /L, with deterioration in renal function (creatinine clearance decreased from 32.91ml/min to 24.9ml/min). The peripheral blood film showed few elliptocytes, fragmented cells, and spherocytes, with moderate polychromasia and anisocytosis with few microcytes. Lactate dehydrogenase was 950u/L (180-380u/L) and serum haptoglobin was <0.1g/L (0.37-2.7g/L). Repeat bone marrow showed a mildly hypocellular marrow with suppression of granulopoiesis, marked erythroid and megakaryocytic hyperplasia. The patient developed seizures and a magnetic resonance imaging of the brain showed T2 hyperintensity involving the following cortical and subcortical white matter regions: left frontal, bilateral occipital, posterotemporal, and posterior parietal lobes ( Fig. 1 ).This was in keeping with posterior reversible encephalopathy syndrome. In view of the presence of microangiopathic haemolytic anaemia, deterioration in renal function, and seizures, the possibility of TTP was entertained. The patient was therefore treated with repeated cycles of plasma exchanges (total of 71 cycles over three months) and continued on IV hydrocortisone 100mg q6H. She was also given four doses of IV vincristine 2mg (bi-weekly over two months) and seven doses of IV rituximab 1g (weekly over a period of two months). However, her TTP remained refractory to medical therapy and plasma exchange, and a decision was made for an autologous HSCT.
Her peripheral blood stem cells were first harvested via apheresis 15 days post IV CyC 2g/m 2 and granulocyte colony stimulating factor (G-CSF). The stem cells were then frozen and un-manipulated. Her conditioning regimen consisted of IV CyC and IV rabbit anti-thymocyte globulin (ATG). IV CyC was given 50mg/kg daily, seven, six, three, and two days before transplantation (total dose of 200mg/ kg). IV ATG was given at a dose of 0.5mg/kg, 1mg/ kg, 1.5mg/kg, and 2.5mg/kg, seven, six, three, and two days respectively prior to transplantation. This was interspersed with her plasma exchanges performed thrice weekly. Her peripheral blood stem cells were then re-infused and she achieved neutrophil engraftment on day 11.
The period post-stem cell transplantation was fraught with recurrent infections such as cytomegalovirus colitis, pneumonias, vulval abscess, and recurrent episodes of neutropenic septicaemia. Post-stem cell transplantion, she was continued on mycophenolate mofetil (MMF), hydroxychloroquine (HCQ), and plasma exchanges thrice weekly. MMF was intermittently stopped during episodes of septicaemia. Her blood pressure, renal function, proteinuria, and TTP gradually showed improvement within a month post-transplantation. Plasma exchanges and MMF were stopped five months post-transplantation. Her disease is now in clinical remission three years later, with therapy consisiting of HCQ 200mg three times a week.
DISCUSSION
Autoimmune diseases, of which SLE is one, are characterised by the breakdown of peripheral and central immune tolerance affecting immune processes, executed by auto-reactive T-and B-cells, subsequently leading to tissue damage and functional loss 1 . The advent of stem cell transplantation for the treatment of autoimmune disease followed observed clinical remissions of autoimmune disease in patients who were transplanted for concomitant haemato-oncological conditions 2 .
SLE is an autoimmune disorder characterised by multisystem microvascular inflammation with the generation of autoantibodies. It is reported that Asians have a higher disease prevalence (27.7-100 patients/100,000 for women) 3 . The specific cause of SLE is unknown, but multiple factors are associated with the development of the disease. These factors include genetic, racial, hormonal, and environmental factors [4] [5] [6] . One of the proposed mechanisms for the development of autoantibodies involves a defect in apoptosis that causes increased cell death and a disturbance in immune tolerance 4, 7, 8 . The redistribution of cellular antigens during necrosis/apoptosis leads to a cellsurface display of plasma and nuclear antigens in the form of nucleosomes. Subsequently, selfintolerant lymphocytes begin targeting normally protected intracellular antigens. The rationale for stem cell transplantation is to attempt to reset the immune system and restore self-tolerance by deleting the auto-reactive lymphocyte clone of haematopoietic origin 9,10 .
Overall 10-year survival rates for SLE range from 83%-93%, but the 15-and 20-year survival rates are lower at 76% and 77%, respectively 11 . Five-year survival rates of 66-97% have been reported in SLE patients in Asia 12, 13 . Major organ involvement and persistent disease activity are predictors of poor outcome 14 . It is noteworthy that at the time of death, at least 50% of patients had active lupus in one study 15 . This suggests that active disease contributed to mortality in a large proportion of patients. To et al identified three distinct clusters with different mortality risks: the standardised mortality rate (SMR) was not increased in patients with mucocutaneous manifestations only (SMR=0.95 (0.5-1.7), p=0.86), but increased sevenfold (SMR=7.23 (6.7-7.7), p<0.001) in those with predominantly renal and haematological manifestations, whilst those with a heterogeneous clinical presentation had a 25% increase in mortality (SMR=1.27 (1.1-1.5), p=0.005) 16 . Bernatsky et al found that the risk of mortality was highest in those aged <40 years (SMR=10.7 [9.5-11.9]), in patients with less than a year of disease duration and in female subjects 17 .
Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 Whilst the introduction of effective immunosuppressive modifying drugs and biologics which have become widely available to treat SLE, stem cell transplantation remains an option for the treatment of refractory SLE, of which HSCT is one of the modalities.
The First International Symposium on Haematopoietic Stem Cell Therapy in Autoimmune Diseases took place in Basel in September 1996, and the consensus was that stem cell transplantation for the treatment of autoimmune diseases should be considered for the following: (1) patients with an increased risk of mortality from their autoimmune disease;
(2) patients not responsive to conventional treatments recommended; (3) before there is irreversible organ damage to achieve maximal clinical benefit 18 . Historically, autologous HSCT was proposed by Marmont et al in 1993, when they demonstrated that haematopoietic stem cells from healthy histocompatible mice were capable of curing murine SLE after eradication of the original haematopoietic stem cells with total body irradiation 19 . Experimental transfer of lupus with bone marrow from SLE-prone mice into normal recipients 20 and the observed clinical remission of SLE after allogeneic or autologous bone marrow transplantation (BMT) in humans 21-23 strongly supported the rationale for exploring BMT as a new treatment for autoimmune diseases 24 .
A non-myeloablative regimen (as opposed to a myeloablative regimen used to treat haematological malignancies) is preferred for HSCT in autoimmune disease as this is associated with reduced mortality 25 . The initial step in autologous HSCT is peripheral blood stem cell mobilisation from the bone marrow after treatment with CyC in combination with G-CSF. Cells expressing the surface antigen CD34 are collected by leukapheresis and cryopreserved. In order to eliminate autoreactive clones, the graft can be manipulated either by negative depletion of T-cells, or positive selection of CD34+ cells. Following mobilisation and harvesting, the patient undergoes a conditioning protocol, which usually consists of a high-dose of cytotoxic agents. Usually, ATG is administered for the eradication of self-reactive T-cells. The graft is then re-infused into the patient and after about 10 days of aplasia, haematopoietic recovery occurs and gradually haematopoiesis is restored.
Post-autologous HSCT, the auto-reactive T-cell clones are eliminated, which is a crucial step in tolerance induction 26, 27 . CD8+ T-lymphocytes, B-cells, and natural killer cells display a rapid and complete reconstitution, while the appearance of CD4+ T-cells are often slowed down. T-cell receptor rearrangement and renewal of the T-cell repertoire gives rise to a non-auto-reactive T-cell repertoire 28 . Besides the generation of naive T-cells and loss of memory cells, modulation of antigen-presenting cells is also seen 26 .
The largest single centre experience for autologous HSCT for SLE to date comes from the Northwestern Memorial Hospital (Chicago, IL, USA), using a nonmyeloablative regimen 29 . 50 patients underwent HSCT for SLE. Mean disease duration was 5.3 years, and 35 of 50 (70%) patients were white. The majority of the patients had cerebritis/myelitis or class III/IV lupus nephritis as an indication for transplantation, and required more than 20mg/ day of prednisone or its equivalent despite use of CyC. Peripheral blood stem cells were mobilised with CyC (2g/m 2 ) and G-CSF at 5μg/kg/day administered subcutaneously daily beginning three days later. The conditioning regimen consisted of IV CyC, 50mg/kg daily, five, four, three, and two days before transplantation (total dose of 200mg/kg) and IV equine ATG 30mg/kg daily, four, three, and two days before transplantation (total dose of 90mg/kg). Conditioning was not started until microbial cultures on the CD34 selected product demonstrated sterility. Broad spectrum antibacterial and antifungal prophylaxis were used. Time to neutrophil engraftment was a mean of nine days (range 7-13 days), and treatment mortality rate was 4%, which is in line with the mortality of autologous transplants for haematological malignancies. Post-HSCT, five-year overall survival was estimated at 84%, with probability of diseasefree survival being 50% at five years. The longest duration of disease remission was 7.5 years.
In addition to decreasing overall lupus activity, HSCT has been shown to reverse pulmonary dysfunction 30 and anti-phospholipid syndrome 31 . HSCT is also associated with clinical responses lasting more than five years on minimal treatment 32 or no treatment 28 . For those that did not achieve sustained remission, clinical benefit was reflected by responsiveness to conventional treatment which had previously failed.
Despite the encouraging results and potential usefulness in refractory SLE, there is a need to Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 consider the potential complications of HSCT (Table 1) , especially in the short-term. In general, the average mortality rate was 7-11% 29, 33 . Problems that can arise post-transplantation include mucositis, prolonged and severe pancytopenia, increased susceptibility to infections 34 and graft versus host disease (GVHD). Oropharyngeal mucositis can sometimes be severe and require intubation if it involves the supraglottic area. Intestinal mucositis can result in malabsorption and diarrhoea and may require temporary parenteral nutrition. Pancytopenia is a common and serious infection which can occur in up to 50% of patients post-transplantation, requiring broad spectrum antibiotics, antifungal and even antiviral therapy. Recombinant haematopoietic growth factors (e.g. filgrastim) are sometimes given to hasten neutrophil recovery. Prophylactic platelet transfusions are initiated in those with thrombocytopaenia, with platelet counts <10 x 10 9 /L due to increased risk of bleeding.
GVHD can be either acute or chronic, and is caused by interaction between the donor and recipient adaptive immunity 35 . The main effectors of inflammation are donor T-cells. Acute GVHD occurs within 100 days post-transplantation, whilst chronic GVHD occurs >100 days post-transplantation. GVHD is a syndrome which may consist of dermatitis, hepatitis, and enteritis, occurring posttransplantation. Cutaneous manifestations of acute GVHD include painful or pruritic maculopapular exanthema over the palms of the hands, soles of the feet, cheeks, neck, ears, and upper trunk, together with fever. The skin lesions are often red to violet in colour. GVHD often causes cholestatic hepatitis, with complications of portal hypertension and liver cirrhosis. Liver biopsy would show chronic hepatitis, bridging necrosis, or liver cirrhosis. Gut involvement often involves the distal small bowel and colon, causing profuse secretary diarrhoea, intestinal bleeding, abdominal pain, and ileus. Patients can develop dysphagia, odynophagia, or loss of weight due to decreased oral intake. A small proportion of patients also develop neuromuscular manifestations such as weakness, neuropathic pain, and muscle cramps. GVHD can also affect the lacrimal glands and salivary glands, causing sicca symptoms.
Is there a role for autologous HSCT for other rheumatological diseases? It appears to be promising in certain other conditions such as rheumatoid arthritis (RA), systemic sclerosis (SSc), and vasculitides. RA rarely has life-threatening complications, and morbidity is predominantly from decreased quality of life due to pain and resultant disability. Even with the advent of DMARDS and biologics such as tumour necrosis factor alpha blockers, rituximab and abatacept, 15-20% of the patients still remain refractory to biologic or DMARD therapy. In a study, 67% of this subset of RA patients reached American College of Rheumatologists 50 criteria for improvement, and Streptococcus viridans iii.
Gram-negative bacilli iv.
Candida species v.
Herpes simplex viruses b. Intermediate (between one to three months post-transplantation) i. Candida species ii.
Pneumocystis jiroveci iii.
Cytomegalovirus species c.
Late (more than three months post-transplantation) i. Encapsulated bacteria ii.
Cytomegalovirus species iv.
Varicella-zoster viruses 4.
Graft versus host disease a. Acute (within 100 days post-transplantation) b. Chronic (100 days post-transplantation) Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 radiological analysis found a reduction in cartilage destruction 36 . Although good initial responses are commonly followed by early relapses, the intensity of the disease activity does not reach the pre-treatment level, and the patient becomes responsive to conventional treatment options again 37, 38 .
SSc is a systemic connective tissue disease of unknown aetiology, often affecting the skin and multiple internal organs, eventually leading to fibrosis 39 . There are two main subgroups, namely diffuse cutaneous SSc and limited cutaneous SSc. The exact mechanisms behind disease development are not fully understood, but recent studies have highlighted the key role of increased T-cell activation and enhanced immune responses driven by various autoantibodies and proinflammatory cytokines 40, 41 . To date, no therapy has been shown to reverse the natural course of the disease 42 . Prognosis for limited SSc is better than for diffuse SSc, with mortality of 5-10% for diffuse SSc versus 1-4% per year for limited SSc 43 . Hence, autologous HSCT has generally been restricted to patients with diffuse SSC. One of the key factors deciding the success of the transplant has been cardiac function. The presence of pulmonary artery hypertension (pulmonary artery systolic pressure more than 40mmHg) 44 , pericardial effusion of more than 1cm on a computed tomography of the chest 45 , evidence of constrictive pericarditis, and tricuspid peak systolic excursion of less than 1.8cm should be considered exclusion criteria for transplantation 46, 47 . With careful patient selection, transplant mortality has been reduced from 9% to 6% 48 . Cutaneous fibrosis has been confirmed histologically to resolve following HSCT 49 , and outcome data also demonstrates HSCT being the single most effective therapy for improving the skin score (decreasing modified Rodnan skin score by 25% or more) 50, 51 . This is important as nontransplant studies have shown that improvement in skin score correlates with improved survival 52, 53 , and hence it is anticipated that improved skin score following autologous HSCT may translate into improved survival. Furthermore, stabilisation of internal organ function has been observed for up to five years after HSCT. Of note is that there was a 72% improvement of skin sclerosis, which was associated with a corresponding reduction in the serum anti-Scl-70 at 36 months after HSCT (r=0.52, p<0.05) 54 . Autologous HSCT, however, does not result in the loss of SSc-associated autoantibodies if previously present, and it remains unclear if the persistent presence of autoantibodies is a predictor of disease relapse 42 .
HSCT in systemic vasculitides also shows promise. A retrospective study described 15 patients who underwent HSCT for systemic vasculitides 55 . Four patients had cryoglobinemia, three had Behcet's, three had granulomatosis with polyangiitis (GPA), whilst the rest of the five patients had a diagnosis of undifferentiated vasculitis, Churg-Strauss angiitis, polychondritis, Takayasu arteritis, and polyarteritis nodosa, respectively. Fourteen patients underwent autologous HSCT, whilst one underwent allogenic HSCT. The overall response to HSCT was 93%, with 46% complete responses, and 46% partial responses. Three patients died; one from advanced disease, one from cancer, and one from GVHD. In another centre, two patients with neurovascular Behcet's disease, one with neurovascular Sjogren's, and one with GPA underwent autologous HSCT for refractory vasculitis after failing the use of CyC 56 . Three patients (one with Behcet's disease, one with Sjogren syndrome, and one with GPA entered remission at six, six, and 24 months, respectively after transplant.
Long-term outcomes of HSCT patients are still unknown, especially in the areas of development of autoimmune thrombocytopaenia, myelodysplastic syndrome, and acute myeloid leukaemia 57 .
CONCLUSION
HSCT may be considered as a treatment option for refractory and severe SLE, and this should be done early in the course of the disease before permanent end organ damage develops. HSCT for SLE should be performed in an experienced centre and a nonmyeloablative regimen should be used. Patients should be aware that there is a high risk of mortality immediately post-HSCT due to pancytopenia, which predisposes the individual to infection and bleeding.
